Corium International, Inc. (NASDAQ:CORI) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

ME Staff 8-k
-
0

Corium International, Inc. (NASDAQ:CORI) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registration.

On March 16, 2018, Corium International, Inc. (“Corium”) sold an additional $20 million aggregate principal amount of 5.00% Convertible Senior Notes due 2025 (the “Notes”). This sale of additional Notes was in connection with the full exercise of the initial purchaser’s 13-day option to the terms of the purchase agreement entered into in connection with Corium’s previously announced offering of up to an aggregate principal amount of $120 million of Notes to qualified institutional buyers to Rule 144A promulgated under the Securities Act of 1933, as amended.

The additional Notes have the same terms as, and are issued under the same indenture as, the $100 million aggregate principal amount of Notes that the Company issued on March 5, 2018 and that are disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 5, 2018, which disclosure is incorporated herein by reference.

Item 2.03. Unregistered Sales of Equity Securities.

The information set forth in Item 2.03 above is incorporated by reference into this Item 2.03.


About Corium International, Inc. (NASDAQ:CORI)

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.